The Welfare of Racing Greyhounds Regulations 2010 are not due for review until after they have been in force for five years, which will be April 2015. However, Defra is beginning to gather evidence on the operation of the regulations now, with a view to completing the review by summer 2015.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2202", "label" : {"_value" : "Biography information for Lord De Mauley"} } , "answeringMemberPrinted" : {"_value" : "Lord De Mauley"} , "dateOfAnswer" : {"_value" : "2014-10-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-10-27T17:50:36.7293091Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2014-10-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Welfare of Racing Greyhounds Regulations 2010"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether they will bring forward the review of the Welfare of Racing Greyhounds Regulations 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"} } , "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"} ], "uin" : "HL2324"} , {"_about" : "http://data.parliament.uk/resources/79517", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/79517/answer", "answerText" : {"_value" : "
It is for NHS England, working with Public Health England (PHE) and other stakeholders, to implement the actions set out in the Cardiovascular Disease (CVD) Outcomes Strategy. NHS England has established a working group with PHE which meets quarterly to discuss progress on the strategy and is taking action on all the recommendations, some it has prioritised over others.<\/p>
<\/p>
For example, on making benchmarked data on CVD risk factors available, PHE has established a CVD National Cardiovascular Intelligence Network and a Partnership Board. These bring together a variety of stakeholders which hold or have an interest in this type of data, including the leads of the existing clinical audits covering cardiovascular disease.<\/p>
<\/p>
PHE also continues to raise awareness of the signs and symptoms of CVD by running campaigns such as Act FAST. This has been the Department\u2019s and PHE\u2019s most successful campaign and continues to help people experiencing the signs and symptoms of a stroke get to hospital quicker. The campaign will be run again during 2014-15.<\/p>
<\/p>
NHS England\u2019s National Clinical Director for Cardiac Disease established a Familial Hypercholesterolaemia (FH) advisory group which has identified some of the barriers to identifying more families with FH and will continue to develop and spread good practice in this field.<\/p>
<\/p>
At a local level, clinical commissioning groups (CCGs) are being encouraged to implement the Strategy with the support of the twelve Strategic Clinical Networks. These networks are working with CCGs and other partners in the health and care system to identify local and regional priorities for cardiac and renal disease, diabetes and stroke.<\/p>
<\/p>
All 152 local authorities are offering the NHS Health Check programme, which aims to present heart disease, stroke, diabetes and kidney disease. Local authorities have a legal duty to deliver the programme to all of their eligible population once every five years. In 2013-14 a total of 2.8 million people (18.5%) of the five years eligible population were offered an NHS Health Check while just fewer than 1.4 million received an NHS Health Check, equating to 49% of those offered. This is the greatest number of NHS Health Checks offerred and received in one year since the programme began.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"} } , "answeringMemberPrinted" : {"_value" : "Earl Howe"} , "dateOfAnswer" : {"_value" : "2014-08-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-08-11T12:24:22.922458Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-07-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cardiovascular Diseases: Health Services"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what progress has been made against each of the actions in their Cardiovascular Disease Outcomes Strategy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"} } , "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"} ], "uin" : "HL1416"} , {"_about" : "http://data.parliament.uk/resources/79518", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/79518/answer", "answerText" : {"_value" : "
<\/p>
The European Union (EU) pet travel scheme (Regulation (EC) No. 998/2003) has made it easier and cheaper for pet owners to travel with their pets and return to the UK. Under the EU scheme pet dogs, cats and ferrets can enter the UK from any country in the world without the need for quarantine providing they meet the strict requirements for entry for the part of the world they are travelling from.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2202", "label" : {"_value" : "Biography information for Lord De Mauley"} } , "answeringMemberPrinted" : {"_value" : "Lord De Mauley"} , "dateOfAnswer" : {"_value" : "2014-07-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-07-28T11:53:14.2421123Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2014-07-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pet Travel Scheme"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the effectiveness of the Pet Travel Scheme in allowing owners to take dogs and cats abroad.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"} } , "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"} ], "uin" : "HL1417"} , {"_about" : "http://data.parliament.uk/resources/79519", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/79519/answer", "answerText" : {"_value" : "
The Department for Education Board is assessed through a board effectiveness evaluation carried out in accordance with the Code of Good Practice of Corporate Governance in Central Government Departments, published in 2011 by HM Treasury and the Cabinet Office.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4270", "label" : {"_value" : "Biography information for Lord Nash"} } , "answeringMemberPrinted" : {"_value" : "Lord Nash"} , "dateOfAnswer" : {"_value" : "2014-07-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-07-28T11:56:35.7649191Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2014-07-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Department for Education"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what arrangements they have in place to assess the performance of the Department for Education Board overall, and of its individual members.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"} } , "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"} ], "uin" : "HL1418"} , {"_about" : "http://data.parliament.uk/resources/79520", "AnsweringBody" : [{"_value" : "Department for Education"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/79520/answer", "answerText" : {"_value" : "
Her Majesty\u2019s Chief Inspector reports to the Education Select Committee at least twice a year on matters relating to Ofsted\u2019s performance.<\/p>
<\/p>
The performance of the Ofsted Chair is reviewed by the Permanent Secretary at the Department for Education on behalf of the Secretary of State.<\/p>
<\/p>
The Chair undertakes performance reviews of the Chief Inspector and Ofsted Board members.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4270", "label" : {"_value" : "Biography information for Lord Nash"} } , "answeringMemberPrinted" : {"_value" : "Lord Nash"} , "dateOfAnswer" : {"_value" : "2014-07-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-07-29T11:19:11.8997409Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "60"} , "answeringDeptShortName" : {"_value" : "Education"} , "answeringDeptSortName" : {"_value" : "Education"} , "date" : {"_value" : "2014-07-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Ofsted"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what arrangements they have in place to assess the performance of the Office for Standards in Education, Children's Services and Skills Board overall, and of its individual members.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"} } , "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"} ], "uin" : "HL1419"} , {"_about" : "http://data.parliament.uk/resources/64118", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/64118/answer", "answerText" : {"_value" : "
NHS England is taking a number of actions to improve the care and management of people with atrial fibrillation (AF). It has published Our Ambition to Reduce Premature Mortality: A resource to support commissioners in setting a level of ambition<\/em>, which identifies improved management of AF as a priority for reducing premature mortality. The resource can be found at:<\/p> <\/p> www.england.nhs.uk/ourwork/sop/red-prem-mort/<\/p> <\/p> National Health Service Improving Quality's Living Longer Lives<\/em> programme includes promoting the use of a simple but effective audit tool called Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) which simplifies the process of identifying patients with AF who are not receiving the right treatment. NHS Improving Quality is currently collaborating with partner organisations, including charities, to support the nationwide roll-out of GRASP-AF.<\/p> <\/p> This work will be supported by the publication of an economic analysis commissioned by NHS Improving Quality using GRASP data which demonstrates both the current and potential impact of atrial fibrillation management on the number of AF related strokes.<\/p> <\/em><\/p> Discussions are also underway to consider whether opportunistic testing for atrial fibrillation (AF) should be encouraged nationally as part of the NHS Health Check programme.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-07-08", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "HL623"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-07-08T15:27:07.0110521Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what action they are taking to improve the diagnosis of atrial fibrillation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
], "uin" : "HL622"}
, {"_about" : "http://data.parliament.uk/resources/64119", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/64119/answer", "answerText" : {"_value" : " NHS England is taking a number of actions to improve the care and management of people with atrial fibrillation (AF). It has published Our Ambition to Reduce Premature Mortality: A resource to support commissioners in setting a level of ambition<\/em>, which identifies improved management of AF as a priority for reducing premature mortality. The resource can be found at:<\/p> <\/p> www.england.nhs.uk/ourwork/sop/red-prem-mort/<\/p> <\/p> National Health Service Improving Quality's Living Longer Lives<\/em> programme includes promoting the use of a simple but effective audit tool called Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) which simplifies the process of identifying patients with AF who are not receiving the right treatment. NHS Improving Quality is currently collaborating with partner organisations, including charities, to support the nationwide roll-out of GRASP-AF.<\/p> <\/p> This work will be supported by the publication of an economic analysis commissioned by NHS Improving Quality using GRASP data which demonstrates both the current and potential impact of atrial fibrillation management on the number of AF related strokes.<\/p> <\/em><\/p> Discussions are also underway to consider whether opportunistic testing for atrial fibrillation (AF) should be encouraged nationally as part of the NHS Health Check programme.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-07-08", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "HL622"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-07-08T15:27:07.6719526Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government, in the light of the publication of the National Institute for Health and Care Excellence clinical guideline 180, what action they are taking to ensure appropriate risk stratification and uptake of anti-thrombotic therapy among patients with atrial fibrillation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
], "uin" : "HL623"}
, {"_about" : "http://data.parliament.uk/resources/64120", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/64120/answer", "answerText" : {"_value" : " Information is not held centrally on the number of people treated with warfarin or novel oral anticoagulants. The following table provides information on the number of prescription items written in England and dispensed in the community in the United Kingdom, for the latest calendar year, for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium.<\/p> <\/p> Prescription items written in England and dispensed in the community in the United Kingdom for 2013 1<\/sup><\/p><\/td><\/tr> Medicine 2<\/sup><\/p><\/td> Items (000s)<\/p><\/td><\/tr> Apixaban<\/p><\/td> 14.4<\/p><\/td><\/tr> Dabigatran etexilate<\/p><\/td> 174.0<\/p><\/td><\/tr> Rivaroxaban<\/p><\/td> 190.0<\/p><\/td><\/tr> Warfarin sodium 3<\/sup><\/p><\/td> 11,022.8<\/p><\/td><\/tr> Total for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium<\/p><\/td> 11,401.2<\/p><\/td><\/tr> Percentage of warfarin sodium compared to the total for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium<\/p><\/td> 96.7%<\/p><\/td><\/tr><\/tbody><\/table> <\/em><\/p> Source:<\/em> ePACT and Hospital ePACT, NHS Prescription Services, part of the NHS Business Services Authority<\/p> <\/em><\/p> Notes:<\/em><\/p> 1. <\/sup>The figures include prescriptions written in a hospital in England but dispensed in the community in the United Kingdom.<\/p> 2. <\/sup>These medicines are also used in secondary care, however no equivalent measure to a prescription item is available for secondary care data.<\/p> Some patients treated with warfarin may receive prescription items for two or three different strengths of warfarin to allow the dose to be altered in response to monitoring of INR. (NB: warfarin is available as 0.5mg, 1mg, 3mg and 5mg tablets).<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-07-01", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "HL625"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-07-01T11:46:45.6126829Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Anticoagulants"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government how many people in England are treated with (1) warfarin, and (2) novel oral anticoagulants each year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
], "uin" : "HL624"}
, {"_about" : "http://data.parliament.uk/resources/64121", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/64121/answer", "answerText" : {"_value" : " Information is not held centrally on the number of people treated with warfarin or novel oral anticoagulants. The following table provides information on the number of prescription items written in England and dispensed in the community in the United Kingdom, for the latest calendar year, for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium.<\/p> <\/p> Prescription items written in England and dispensed in the community in the United Kingdom for 2013 1<\/sup><\/p><\/td><\/tr> Medicine 2<\/sup><\/p><\/td> Items (000s)<\/p><\/td><\/tr> Apixaban<\/p><\/td> 14.4<\/p><\/td><\/tr> Dabigatran etexilate<\/p><\/td> 174.0<\/p><\/td><\/tr> Rivaroxaban<\/p><\/td> 190.0<\/p><\/td><\/tr> Warfarin sodium 3<\/sup><\/p><\/td> 11,022.8<\/p><\/td><\/tr> Total for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium<\/p><\/td> 11,401.2<\/p><\/td><\/tr> Percentage of warfarin sodium compared to the total for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium<\/p><\/td> 96.7%<\/p><\/td><\/tr><\/tbody><\/table> <\/em><\/p> Source:<\/em> ePACT and Hospital ePACT, NHS Prescription Services, part of the NHS Business Services Authority<\/p> <\/em><\/p> Notes:<\/em><\/p> 1. <\/sup>The figures include prescriptions written in a hospital in England but dispensed in the community in the United Kingdom.<\/p> 2. <\/sup>These medicines are also used in secondary care, however no equivalent measure to a prescription item is available for secondary care data.<\/p> Some patients treated with warfarin may receive prescription items for two or three different strengths of warfarin to allow the dose to be altered in response to monitoring of INR. (NB: warfarin is available as 0.5mg, 1mg, 3mg and 5mg tablets).<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-07-01", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "HL624"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-07-01T11:46:44.903613Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Anticoagulants"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what percentage of the total number of prescriptive items for apixaban, dabigatran etexilate, rivaroxaban, and warfarin sodium in England were for warfarin sodium in the last year for which figures are available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
], "uin" : "HL625"}
, {"_about" : "http://data.parliament.uk/resources/64122", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/64122/answer", "answerText" : {"_value" : " Decisions on the prescribing of medicines are a matter for clinicians in discussion with their patients.<\/p> <\/p> National Health Service commissioners are legally required by regulations to fund those anticoagulant treatments recommended by the National Institute for Health and Care Excellence(NICE) in its technology appraisal guidance.<\/p> <\/p> The NICE Implementation Collaborative published a consensus statement on supporting the use of novel oral anticoagulants in non-valvular atrial fibrillation on 18 June 2014. This is available at:<\/p> <\/p> www.nice.org.uk/resource/CG180/pdf/c/cg180-atrial-fibrillation-nic-consensus-statement-on-the-use-of-noacs?id=gvyb3hjdqrcjtn6ytpwx3ydb64<\/p> <\/p> NICE published its updated clinical guideline on the management of atrial fibrillation on 25 June 2014 which recommends that novel oral anticoagulants should be offered where appropriate.<\/p> <\/p> The latest data from the Innovation Scorecard show that uptake of new anticoagulants across England is increasing. Further information is available at:<\/p> <\/p> www.hscic.gov.uk/catalogue/PUB13669<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
}
, "answeringMemberPrinted" : {"_value" : "Earl Howe"}
, "dateOfAnswer" : {"_value" : "2014-07-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-07-01T11:47:28.0313192Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-06-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Anticoagulants"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government what action they are taking to increase the uptake of novel oral anticoagulants in the management of atrial fibrillation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4171", "label" : {"_value" : "Biography information for Lord Black of Brentwood"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Black of Brentwood"}
], "uin" : "HL626"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Lord+Black+of+Brentwood&_page=1&max-answer.dateOfAnswer=2014-10-27", "page" : 0, "startIndex" : 1, "totalResults" : 13, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}